Allii Macrostemonis Bulbus Veterinary Grade API is supplied as a milled dry powder whose batch-to-batch marker content, moisture burden, and microbial load govern downstream dosage-form design. In large-scale feed mills, the powder is introduced as a medicated premix intermediate rather than as direct crude botanical material. The receiving facility pre-blends the API with a chemically inert carrier such as ground corn cob or calcium carbonate to a final inclusion of 0.5% to 5.0% w/w, adjusted against the marker standardization stated in the certificate of analysis. The mixture is hammer-milled through a 250 µm screen and transferred to a twin-ribbon blender with a working volume of 500–2000 L; after 15 min at 20 rpm, the coefficient of variation across 10 sampling points should remain below 5%, consistent with the homogeneity expectations of Regulation (EC) No 183/2005 for feed hygiene and EU Regulation (EU) 2019/6 for veterinary medicinal products. Incoming botanical material is tested according to USP <561> for pesticide residues, heavy metals, and foreign organic matter, with elemental impurities controlled under USP <232>/<233> where pharmacopoeial harmonization applies. Storage is maintained at 25 °C and 35% RH in multi-wall paper bags with an inner polyethylene liner to limit hygroscopic gain and marker degradation. When the premix is subsequently pelleted, the mass temperature during steam conditioning at 70–85 °C may reduce the sulfur-containing volatile fraction; retention time is therefore limited to 20–30 s, and post-pellet cooling to below 35 °C is completed before bulk bin transfer. The terminal product is a 25 kg multi-wall bag or 1 t bulk container intended solely for in-feed medication in those jurisdictions where the botanical API is registered for veterinary use.

Does Low Dispersibility in Hard Water Restrict Drinking Water Delivery?

Formulation as a drinking-water soluble powder is appropriate only when the milled API is co-processed with a wetting agent and a pH buffer; the API alone settles rapidly in hard water having total hardness above 250 mg/L as CaCO₃. The dry blend is milled to a particle size of D90 < 180 µm on a spiral jet mill and mixed with anhydrous sodium citrate and lactose monohydrate at an API-to-diluent ratio of 1:4 to 1:9 w/w. A stock solution is prepared at 1:100 or 1:128 through a proportioner pump, and the final drinking water concentration is derived from the standardized marker content per kg body weight, then verified by an in-use stability study over 24 h. Foaming during reconstitution is controlled by de-aeration under reduced pressure or by slow powder addition into a continuous vortex. Compliance for this presentation is governed by VICH GL18(R2) for residual solvents, USP <61>/<62> for microbial enumeration, and the relevant compendial monograph for the formulated powder. Oxidative loss of the volatile sulfur fraction is reduced by nitrogen-flushed primary packaging; once dispersed, any unused medicated water is discarded after 24 h to limit sedimentation and microbial overgrowth. The terminal product is a 100 g or 1 kg foil-laminated moisture-barrier pouch with an induction-sealed opening device.

The injectable presentation imposes thermodynamic and particulate constraints absent from oral forms. A sterile solution is prepared only from a highly purified dry fraction with controlled lipopolysaccharide burden; the bulk solids are dissolved in water for injection, adjusted to pH 6.8–7.2 with 0.1 M phosphate buffer, and filtered through a 0.22 µm polyethersulfone membrane prior to aseptic filling. Terminal sterilization is accomplished by moist-heat autoclaving at 121 °C for 15 min, consistent with the sterility assurance expectations of USP <71>. Endotoxin control follows USP <85>; for a 100 kg swine receiving a dose of 0.1 mL/kg, the calculated K/M limit is 5 EU/kg divided by 0.1 mL/kg, or 50 EU/mL, before release. Particulate matter is monitored by the light obscuration method of USP <788> for small-volume injectables, with compendial limits applied to particles ≥10 µm and ≥25 µm. Residual solvent evaluation follows VICH GL18(R2), particularly when the dry fraction is obtained by ethanolic extraction; residual ethanol is controlled according to the ICH Q3C Class 3 solvent limit. Steroidal saponin-rich fractions may precipitate below pH 6.5 and are not combined with cationic antimicrobials or strongly oxidizing additives without prior compatibility screening. The terminal package is a 10 mL amber Type I glass vial under nitrogen headspace. Published long-term stability data for this specific botanical injectable configuration is limited; therefore, each batch is placed on a bracketed real-time stability protocol and is not released beyond the validated shelf-life period.

Tablet and intraruminal bolus compression: moisture uptake and friability boundaries

Direct compression of the crude powder alone is generally unsuitable because saponin-rich botanical material develops sticky surfaces above 60% relative humidity. The preferred route is wet granulation with povidone K30 at 3–5% w/w of dry granulate and an aqueous ethanol granulating fluid; the wet mass is dried at 50 °C in a fluid-bed dryer until loss on drying is below 3%. A representative tablet formula contains API at 20–30% w/w, microcrystalline cellulose at 35–50% w/w, lactose monohydrate as brittle filler, crospovidone at 3% w/w as disintegrant, colloidal silicon dioxide at 0.5% w/w as glidant, and magnesium stearate at 0.5–1.0% w/w as lubricant. Compression is performed on a rotary tablet press at 8–15 kN for small tablets; large intraruminal boluses are compressed on a hydraulic press with flat-faced tooling. Hardness for standard tablets is controlled between 50–100 N; bolus hardness is maintained between 150–250 N. Friability is tested according to USP <1216> and should remain below 1%, while disintegration for immediate-release tablets follows USP <701> with a limit of not more than 30 min in water at 37 °C. If relative humidity in the compression suite exceeds 60%, the powder bed is pre-dried and the run is paused for moisture checks; pick-stick and edge chipping increase otherwise. The terminal product is a 500 mg to 5 g scored tablet or bolus packed in HDPE containers with a desiccant.

When Capsule Filling Machinery Is Operated Above 40% RH, Powder Flow Diverges

For companion animal unit-dose administration, the milled API is filled into two-piece capsules only after dry blending to a target angle of repose below 40° as measured by the fixed-funnel method of USP <1174>. The API is premixed with anhydrous dibasic calcium phosphate and mannitol at a ratio of 1:3 to 1:6 w/w; fumed silica at 0.5–1.0% w/w is added as a glidant. The blend is filled on a tamping-pin capsule machine at 20,000–75,000 capsules/h depending on capsule size; blend uniformity is checked under USP <905> and the early-stage relative standard deviation is kept below 5% before machine fill. Capsule shell selection is moisture-dependent: gelatin capsules are not used when the fill moisture exceeds 5% or when storage conditions exceed 25 °C and 60% RH; HPMC capsules are substituted to reduce crosslinking risk. The terminal product is a 250 mg to 1 g filled capsule in PVC/PVdC blister or HDPE bottle with silica gel. An end-of-run disintegration check is performed by USP <701> and should be complete within 45 min for capsules.

Directly granulated batches are used for oral top-dressing in horses and calves when flow into feed or molasses is required. The API is combined with lactose monohydrate and low-viscosity hydroxypropyl cellulose binder at 2% w/w in a high-shear granulator; impeller speed is 300–500 rpm and wet massing time is 3–6 min. Granules are dried in a fluid bed at 50–60 °C to a moisture content below 2%. The target granule size is 300–850 µm, with fines below 150 µm limited to 10% w/w to reduce segregation during top-dressing. A representative batch contains 30–50% w/w API, with the balance composed of filler, binder, and up to 1% anti-caking agent. Particle size distribution is verified by sieve analysis according to ISO 2591-1; uniformity of mass of single-dose preparations is tested by Ph. Eur. 2.9.5 where granules are filled into sachets. Microbial quality is tested under USP <61>/<62>, and the absence of Salmonella and Escherichia coli is required for oral administration. For administration, the granules may be top-dressed or dispersed in water at 1:10 w/v immediately before use; any dispersed batch not consumed within 2 h is discarded. The terminal product is a 100 g or 500 g graduated polypropylene jar with an induction-sealed closure.